Dupixent 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FJG8J
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $46,537
Award facts
- Contract value 100% obligated
- $46,536.71 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 8, 2026, the Defense Logistics Agency awarded a $46,536.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes. This non-set-aside contract, which will be completed by January 9, 2026, represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical. Cencora's primary IDC, valued at up to $999,999,999.00 and extending through December 31, 2031, serves as the comprehensive vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the operating subsidiary responsible for fulfilling this delivery order.
Dupixent is a specialty biologic medication used in the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis, making it a critical pharmaceutical commodity for military treatment facilities and veterans' healthcare programs. The delivery order reflects DLA's ongoing procurement strategy under its Pharmaceutical Prime Vendor Global Program, which leverages established contracts to efficiently supply essential medical products to federal healthcare systems. As a competitively awarded contract with no set-aside designation, this award demonstrates AmerisourceBergen's continued capability to meet federal procurement requirements for specialized pharmaceutical products through open competition.
Quick answers
Who was awarded contract SPE2DR26FJG8J?
SPE2DR26FJG8J was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FJG8J worth?
The government has obligated $46,537 on SPE2DR26FJG8J.
Is contract SPE2DR26FJG8J an order under another contract?
Yes. SPE2DR26FJG8J is a delivery order under SPE2DR25D1106, an indefinite delivery contract.
Was contract SPE2DR26FJG8J competed?
The extent of competition for SPE2DR26FJG8J was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award